- Home
- KTTA vs CIF Comparison
KTTA vs CIF Comparison
Compare KTTA & CIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KTTA | CIF |
|---|---|---|
| Founded | 2020 | 1988 |
| Country | United States | United States |
| Employees | 4 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 29.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KTTA | CIF |
|---|---|---|
| Price | $0.86 | $1.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 111.1K | 39.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.11% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $1.52 |
| 52 Week High | $2.34 | $1.82 |
Technical Indicators
Market Signals| Indicator | KTTA | CIF |
|---|---|---|
| Relative Strength Index (RSI) | 57.65 | 37.67 |
| Support Level | $0.67 | N/A |
| Resistance Level | $0.90 | $1.73 |
| Average True Range (ATR) | 0.06 | 0.02 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 94.76 | 25.00 |
Price Performance
Historical ComparisonAbout KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
About CIF MFS Intermediate High Income Fund
Mfs Intermediate High Income Fund is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income, but it may also consider capital appreciation. The fund invests a majority of its net assets, including borrowings for investment purposes, in high-income debt instruments. Its portfolio of investments includes investment-grade corporate bonds, government securities and other securities. The portfolio includes Midstream, Financial Institutions, Energy, Cable TV, and Utilities.